Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer

by T.S. Uldrick, M.A. ‘Mac’ Cheever, P.H. Gonçalves, S. Fling, K. Aleman, B. Emu, M.S. Ernstoff, R. Gorelick, J. Kaiser, H. E Kohrt, A. Lacroix, M. Lindsley, L. M Lundgren, K. Lurain, F. Maldarelli, C. Parsons, E. Sharon, A. Widell, R. Yarchoan
Published 2017-12-01